41 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp01180 | Apo E | LRVRLASHLRKLRKRLLRDADDLQKRLAVY | Apoprotein E | Cell membrane disintegration | MTT/MTS assay | PANC-1 | Pancreatic cancer | 55 % Cytotoxity at 40 µg/ml |
| dbacp01896 | BPC194 | KKLKKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | Panc-1 | Cervical cancer | IC50 : 40.0 ± 3 Μm |
| dbacp01901 | BPC88 | KKLLKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | Panc-1 | Cervical cancer | IC50 : 32.5 ± 11 μM |
| dbacp01906 | BPC96 | LKLKKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | Panc-1 | Cervical cancer | IC50 : 51.0 ± 6 Μm |
| dbacp01911 | BPC98 | LLKKKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | Panc-1 | Cervical cancer | IC50 : 44.5 ± 0.7 Μm |
| dbacp02690 | Dermaseptin-PH | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | PANC-1 | Pancreatic cancer | IC50 : 17.44 - 49.51 μM |
| dbacp02713 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Brain tumor | IC50 : 28.95 μM |
| dbacp02714 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Breast cancer | IC50 : 28.95 μM |
| dbacp02715 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Pancreatic cancer | IC50 : 28.95 μM |
| dbacp02716 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Lung cancer | IC50 : 28.95 μM |
| dbacp02717 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Prostate cancer | IC50 : 28.95 μM |
| dbacp02733 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Brownbelly leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | PANC-1 | Pancreatic cancer | IC50 : 8.64 - 18.51 μM |
| dbacp02738 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Skin secretion, Brownbelly leaf frog, Purchased in Peru, South America | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | PANC-1 | Pancreatic cancer | IC50 : 8.64 - 18.51 μM |
| dbacp02778 | Disintegrin metalloproteinase/disintegrin echistatin | IGIAYNRGMCDPKKSVGTVMDHSTEHLSVAVAMAHEMGHNLGMDHDGNQCNCGGAGCVMSEELIESRSYKFSDCSKNQYQNYLTIYKPQCILNQPLRTDTVSTPVSGNELLQNSANPCYDPLTCHPREGEQCESGPCCRNCKFLKEGTICKRARGDDMDDYCNGKTCDCPRNPHKGPATAKGSVLM | Saw-scaled viper | Membrane-disruption | Transwell migration assay | Panc-1 | MG human glioblastoma | IC50 : 154.5 μM |
| dbacp03505 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Brain tumor | IC50 : 11.17μM |
| dbacp03506 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Breast cancer | IC50 : 11.17μM |
| dbacp03507 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Pancreatic cancer | IC50 : 11.17μM |
| dbacp03508 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Lung cancer | IC50 : 11.17μM |
| dbacp03509 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Prostate cancer | IC50 : 11.17μM |
| dbacp06203 | TAT-CTMP4 | LDPKLMKEEQMSQAQLFTRSFDDGL | Not found | Inducing apoptosis | Not specified | Panc-1 | Pancreatic cancer | TAT-CTMP4 induced a dose-dependent increase in apoptosis as detected by %-TUNEL positive cells and %-active caspase-3 (% active caspase-3 ranged from 31.2 to 61.9 at the highest dose tested (10 µM). |
| dbacp06884 | trichoderin A | MDA-P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderma sp. fungus, strain 05FI48 | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 0.3 μM |
| dbacp06893 | trichoderin A analogue 4 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 0.5 μM |
| dbacp06894 | trichoderin A analogue 12 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 > 9 μM |
| dbacp06895 | trichoderin A analogue 13 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 6.0 μM |
| dbacp06896 | trichoderin A analogue 14 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 1.8 μM |
| dbacp06897 | trichoderin A analogue 15 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 0.9 μM |
| dbacp06898 | trichoderin A analogue 16 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 0.5 μM |
| dbacp06899 | trichoderin A analogue 17 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 0.6 μM |
| dbacp06900 | trichoderin A analogue 18 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 0.2 μM |
| dbacp06901 | trichoderin A analogue 19 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 0.2 μM |
| dbacp07853 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Phyllomedusa tarsius | Membrane disruption and cationic enhancement | MTT assay | PANC-1 | Pancreatic Cancer | IC50 = 28.95 µM |
| dbacp07858 | K8, 23-DPT9 | GLWSKIKKAAKTAGKAALGFVNKMV | Synthetic | Membrane disruption and cationic enhancement | MTT assay | PANC-1 | Pancreatic Cancer | IC50 = 11.17 µM |
| dbacp07881 | Nubein6.8 | LKCNQLIPPFWKTCPKGKNLCYKMTMRAAPMVPVKRGCIDVCPKSSLLIKYMCCNTDKCN | Naja nubiae | DNA damage and apoptosis induction | MTT assay | PANC-1 | Pancreatic Cancer | slight toxicity above 3.7 μM |
| dbacp07882 | 0Dap | GIKKWLHSAKKFGKKFVKKIZNS | Synthetic | Not Available | WST-1 assay | PANC-1 | Pancreatic Cancer | EC50 = 9.1±0.3 μM |
| dbacp07883 | 2Dap | GIKXWLHSAKKFGXKFVKKIZNS | Synthetic | Not Available | WST-1 assay | PANC-1 | Pancreatic Cancer | EC50 = 14.7±0.6 μM |
| dbacp07884 | 4Dap | GIKXWLHSAXKFGXKFVKXIZNS | Synthetic | Not Available | WST-1 assay | PANC-1 | Pancreatic Cancer | EC50 = 35.7±0.7 μM |
| dbacp07885 | 6Dap | GIKXWLHSAXXFGXKFVXXIZNS | Synthetic | Not Available | WST-1 assay | PANC-1 | Pancreatic Cancer | EC50 = 55.0±1.8 μM |
| dbacp07886 | 8Dap | GIXXWLHSAXXFGXXFVXXIZNS | Synthetic | Not Available | WST-1 assay | PANC-1 | Pancreatic Cancer | EC50 = 61.4±0.7 μM |
| dbacp08041 | Silk Fibroin peptide | Not Available | Silkworm Cocoons | SFP induces S-phase cell-cycle arrest | MTT assay | PANC-1 | Pancreatic Cancer | IC50 = 8.224 ± 1.43 mg/ml |
| dbacp08046 | R11-NLS-pep8 | RRRRRRRRRRRIKKKRKWEASALVCIRLVTSSKPRTVa | NKp44 derived synthetic peptide | NKp44-pep8 inhibits PCNA function | PrestoBlue assay | PANC-1 | Pancreatic Cancer | ED50 = 7.8 μM |
| dbacp08435 | Alpha-gliadin peptide p31-43 | LGQQQPFPPQQPY | Synthetic | Not Available | MTT assay | PANC-1 | Pancreatic Cancer | 26.2% growth inhibition at 70 μg/mL |